Loading...
•
Jun 30
•/
GSK Q2 2025 Earnings Report
GSK reported strong Q2 performance with solid revenue growth and EPS expansion driven by Specialty Medicines.
Key Takeaways
GSK posted a robust quarter with £7.99 billion in revenue and £1.89 billion in net income. EPS rose to 46.5p as operating profit margins improved, supported by growth in Specialty Medicines and pipeline progress.
Revenue reached £7.99 billion, up from £7.88 billion last year
EPS rose to 46.5p from 43.4p, driven by improved margins
Net income totaled £1.89 billion in the quarter
Cash generated from operations grew to £3.73 billion
GSK
GSK
GSK Revenue by Segment
GSK Revenue by Geographic Location
Revenue by Segment
Specialty Medicines Revenue
CapyFin.comVaccines Revenue
CapyFin.comGeneral Medicines Revenue
CapyFin.comRevenue by Geographic Location
US Revenue
CapyFin.comEurope Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
GSK expects to deliver toward the top end of FY2025 guidance, driven by strong Specialty Medicines performance, robust pipeline momentum, and improved operational efficiency.
Positive Outlook
- FY2025 sales guidance reaffirmed at 3–5% growth
- Core EPS expected to grow 6–8%
- Specialty Medicines growth upgraded to low teens %
- HIV portfolio forecast raised to mid-to-high single digit %
- Strong cash flow supports investment and shareholder returns
Challenges Ahead
- Vaccines guidance revised to low single digit decline to stable
- General Medicines expected to remain broadly stable
- R&D costs expected to grow ahead of sales
- Currency headwinds projected to impact Sterling results by ~4%
- Remaining Zantac litigation settlement costs expected in H2
Revenue & Expenses
Visualization of income flow from segment revenue to net income